Glimepiride & Metformin Hydrochloride Prolonged Release Tablets IP - AMARIN M3 Tablets

AMARIN M3 Tablets
Composition:- Glimepiride 3 mg + Metformin 500 mg

AMARIN M3 Tablets – Glimepiride & Metformin Hydrochloride Prolonged Release Tablets IP combine Glimepiride, a sulfonylurea that stimulates pancreatic insulin secretion, with Metformin Hydrochloride (Prolonged Release), which reduces hepatic glucose production and enhances peripheral insulin sensitivity. The prolonged-release (PR) formulation of Metformin ensures gradual drug absorption, providing stable glycemic control with fewer gastrointestinal side effects compared to immediate-release Metformin. This dual mechanism offers a synergistic approach to managing blood glucose in T2DM patients.

Key Points of Glimepiride & Metformin Hydrochloride Prolonged Release Tablets IP – AMARIN M3 Tablets
• Dual Mechanism for Better Control: Glimepiride and Metformin work together to regulate blood sugar through complementary pathways for enhanced glycemic management.
• Prolonged-Release Formulation: Metformin PR provides sustained glucose control throughout the day while minimizing gastrointestinal discomfort.
• Reduced Hypoglycemia Risk: Glimepiride, when appropriately dosed in combination with Metformin, has a lower likelihood of causing hypoglycemia compared to other sulfonylureas.

Can be Prescribed by:
• Endocrinology
• Diabetology
• Internal Medicine / General Medicine
• Family Physicians / Primary Care Providers
• Healthcare practitioner

Disclaimer: To be used under medical supervision only. Not intended for general public promotion. This content is meant for registered healthcare professionals only.